Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL736059

CCS(=O)(=O)N1CC2(CCN(c3ccc(OCCCN4CCCCC4)cc3)CC2)c2cc(F)ccc21.O=C(O)C(F)(F)F

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CACNA1B Q00975 2/20 0.44
HRH3 Q9Y5N1 12/20 0.43
KCNH2 Q12809 4/20 0.43
HRH1 P35367 4/20 0.40
HTR2A P28223 4/20 0.40
HTR1A P08908 3/20 0.40
DRD2 P14416 3/20 0.40
DRD3 P35462 3/20 0.40
TMEM97 Q5BJF2 2/20 0.40
SIGMAR1 Q99720 2/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 1/20 0.40
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
NPY5R Q15761 1/20 0.39
CYP3A4 P08684 1/20 0.39
DRD1 P21728 1/20 0.39
DRD5 P21918 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL737532 0.90 CACNA1B (0.51) CACNA1BHRH3KCNH2HRH1POLB
Trifluoroacetic Acid SCHEMBL737856 0.86 CACNA1B (0.45) CACNA1BHRH3KCNH2HRH1POLB
Trifluoroacetic Acid SCHEMBL737131 0.83 CACNA1B (0.52) CACNA1BHRH3KCNH2HRH1POLB
Trifluoroacetic Acid SCHEMBL738381 0.76 HRH3 (0.61) HRH3KCNH2HRH1HTR2AHTR1A
Trifluoroacetic Acid SCHEMBL737082 0.75 HRH3 (0.47) CACNA1BHRH3KCNH2HRH1HTR2A
Trifluoroacetic Acid SCHEMBL737064 0.74 HRH3 (0.46) CACNA1BHRH3KCNH2HRH1HTR2A
Trifluoroacetic Acid SCHEMBL736519 0.73 HRH3 (0.55) CACNA1BHRH3KCNH2HRH1POLB
Trifluoroacetic Acid SCHEMBL735635 0.73 HRH3 (0.57) CACNA1BHRH3KCNH2HRH1POLB
Trifluoroacetic Acid SCHEMBL735794 0.72 ALDH1A1 (0.56) CACNA1BHRH3KCNH2POLBMAPT
Trifluoroacetic Acid SCHEMBL737443 0.72 HRH3 (0.60) CACNA1BHRH3KCNH2HRH1HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138206-B2 Piperidine derivative MSD. K.K. (JP) 2012-03-20 US claimed
US-20090137576-A1 Novel Piperidine Derivative MSD K.K. (JP) 2009-05-28 US claimed
EP-1892241-A1 NOVEL PIPERIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-02-27 EP claimed
US-8138206-B2 Piperidine derivative MSD. K.K. (JP) 2012-03-20 US disclosed
US-20090137576-A1 Novel Piperidine Derivative MSD K.K. (JP) 2009-05-28 US disclosed
EP-1892241-A1 NOVEL PIPERIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-02-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137576-A1 Novel Piperidine Derivative HRH4, HRH3, HRH1 CACNA1B 615/4885HRH3 2/4885KCNH2 308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.